229 related articles for article (PubMed ID: 28762388)
1. Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.
Blick C; Ritchie AWS; Eisen T; Stewart GD
Nat Rev Urol; 2017 Dec; 14(12):753-759. PubMed ID: 28762388
[TBL] [Abstract][Full Text] [Related]
2. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for high-risk renal cell carcinoma patients.
Kunkle DA; Haas NB; Uzzo RG
Curr Urol Rep; 2007 Jan; 8(1):19-30. PubMed ID: 17239313
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
5. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
6. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery.
Capitanio U; Necchi A; Larcher A; De Cobelli F; Montorsi F
Eur Urol Oncol; 2018 Dec; 1(6):538-539. PubMed ID: 31158101
[No Abstract] [Full Text] [Related]
10. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
Berquist SW; Yim K; Ryan ST; Patel SH; Eldefrawy A; Cotta BH; Bradshaw AW; Meagher MF; Bindayi A; McKay RR; Autorino R; Staehler M; Derweesh IH
Int J Urol; 2019 May; 26(5):532-542. PubMed ID: 30943578
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic opportunities in metastatic renal cell carcinoma].
Buess M
Praxis (Bern 1994); 2009 Apr; 98(9):481-6. PubMed ID: 19404907
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
Chaudhary UB; Hull GW
Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
[TBL] [Abstract][Full Text] [Related]
14. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
Messina C; Zanardi E; Boccardo F
Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
[TBL] [Abstract][Full Text] [Related]
15. Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma.
Kapoor A; Kim J; Goucher G; Hoogenes J
Urol Clin North Am; 2020 Aug; 47(3):271-280. PubMed ID: 32600530
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review of the Management of Local Kidney Cancer Relapse.
Kriegmair MC; Bertolo R; Karakiewicz PI; Leibovich BC; Ljungberg B; Mir MC; Ouzaid I; Salagierski M; Staehler M; van Poppel H; Wood CC; Capitanio U;
Eur Urol Oncol; 2018 Dec; 1(6):512-523. PubMed ID: 31158097
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
18. Multimodality treatment of metastatic renal cell carcinoma.
Mickisch GH
Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
[TBL] [Abstract][Full Text] [Related]
19. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
20. Urologic approaches to metastatic renal cell carcinoma.
Mickisch GH
Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
